Atellica® CH
Analyzer

SIEMENS Healthineers

Assay Chart

This document applies to system software version 1.24. Assay availability is dependent on regulatory status in each country.

The Instructions For Use (IFU) is the primary source for assay details and should always be consulted for the most up-to-date information.

Assay (TDef name)	Test definition version	Test per well	Test Duration (min)	Reagent Onboard Well Stability (days)	Reagent Storage Temp	Sample Types	Reagent pack chimney	Sample Volume (µL)	Assay Reaction			Assay Ranges				Calibration			
									Assay Principle	Reaction Type	Wavelength (λ)	Assay Measuring Interval	Expected Values	Onboard Dilution Factor	Extended Range	Calibrator Name	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)
Acetaminophen (Acet)	1.2	150	10.0	14	2–8°C	S;Li Hep P	Yes	6.0	Colorimetric: acyl amidohydrolase	EPA	596, 805	0.2–20.0 mg/dL (13.2–1322.0 µmol/L)	1.0–2.0 mg/dL (66.0–132.0 µmol/L)	3	0.2–60.0 mg/dL (13.2–3966.0 µmol/L)	TOX CAL	3	62	1
Alanine Aminotransferase (ALT)	1.8	425	10.0	90	2–8°C	S;Li Hep P	No	25.0	Modified IFCC	ENZ	340, 410	7–1100 U/L	10–49 U/L	3	3300 U/L	ENZ 2 CAL	30	131	30
Alanine Aminotransferase P5P (ALTPLc)	1.3	520	10.0	19†	2–8°C	S;Li Hep P	No	25.0	IFCC	ENZ	340, 410	9–1000 U/L	7–40 U/L	6	6000 U/L	ENZ 2 CAL	30	130	4
Albumin BCG (Alb)	1.2	850	10.0	60	15–25°C	S;Li Hep P	No	2.0	Dye Binding: bromocresol green	EPA	596, 694	1.0–6 g/dL (10–60 g/L)	3.2–4.8 g/dL (32–48 g/L)	2	12.0 g/dL (120 g/L)	CHEM CAL	2	97	60
Albumin BCP (AlbP)	1.2	800	3.0	20	2–8°C	S;Li Hep P;K EDTA P	No	4.0	Dye Binding: bromocresol purple	EPA	596, 694	0.5–8 g/dL (5–80 g/L)	3.4–5.0 g/dL (34–50 g/L)	—	—	AlbP CAL	8 hrs	30	8
Alkaline Phosphatase, Concentrated (ALP_2c)	1.1	600	8.0	30	2–8°C	S;Li Hep P	Yes	10.0	IFCC Standardization	ENZ	410, 478	10–1000 U/L	46–116 U/L	2.3	10–2300 U/L	ALP_2 CAL	30	60	17
Alpha-1-acid Glycoprotein (AAG)	1.4	100	10.0	30	2–8°C	S;Li Hep P;K EDTA P	Yes	3.2	PEG-enhanced immunoturbidimetric	EPA	340, 596	5.0–612.0 mg/dL (0.05–6.12 g/L)	58.2–154.8 mg/dL (0.58–1.55 g/L)	3	5.0–1836 mg/dL (0.05–18.36 g/L)	LSP CAL	28	60	14
Alpha-1-antitrypsin (AAT)	1.2	90	10.0	30	2–8°C	S;Li Hep P	No	2.7	PEG-enhanced immunoturbidimetric	EPA	340, 596	5–500 mg/dL (0.05–5.00 g/L)	78–200 mg/dL (0.78–2.00 g/L)	2	1000 mg/dL (10.0 g/L)	LSP CAL	28	60	7
Ammonia (Amm)	1.6	60	10.0	30	2–8°C	Li Hep P;K EDTA P	No	25.0	Enzymatic	RRA	340, 694	17–1277 µg/dL (10–750 µmol/L)	19–54 µg/dL for adults (11–32 µmol/L for adults)	2	17–2554 µg/dL (10–1499 µmol/L)	CHEM III CAL	30	30	3
Amylase (Amylas (serum, plasma))	1.2	175	9.0	30	2–8°C	S;Li Hep P	No	16.0	Ethylidene Blocked-pNPG7	ENZ	410, 694	5–1500 U/L	30–118 U/L	3	4500 U/L	—	—	—	1
Amylase (Amylas (urine))	1.2	175	9.0	30	2–8°C	Urine	No	16.0	Ethylidene Blocked-pNPG7	ENZ	410, 694	5–1500 U/L	≤ 650 U/L	3	4500 U/L	—	—	—	1

Siemens Healthcare Diagnostics Inc., 511 Benedict Ave.,Tarrytown, NY 10592-5097 USA
11484427 Rev. 03 2022-02

Assay (TDef name)	Test definition version	Test per well	Test Duration (min)	Reagent Onboard Well Stability (days)	Reagent Storage Temp	Sample Types	Reagent pack chimney	Sample Volume (µL)	Assay Reaction			Assay Ranges				Calibration			
									Assay Principle	Reaction Type	Wavelength (λ)	Assay Measuring Interval	Expected Values	Onboard Dilution Factor	Extended Range	Calibrator Name	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)
Amylase_2 (AMY_2)	1.1	175	9.0	31	2–8°C	S;Li Hep P;Urine	No	16.0	Ethylidene Blocked-pNPG7	ENZ	410, 694	20–1500 U/L	Serum and plasma: 30–118 U/L Urine: ≤ 650 U/L	3	20–4500 U/L	SPCL CHEM CAL	7	62	31
Anti-Streptolysin-O_2 (ASO_2)	1.1	200	10.0	30	2–8°C	S;Li Hep P;K EDTA P	No	7.5	Latex-enhanced immunoturbidimetric	EPA	571	25.0–1000 IU/mL	Children (preschool) ≤ 100.0 IU/mL Children (school age)≤ 250.0 IU/mL Adults≤ 200.0 IU/mL Siemens–determined adult reference range ≤ 194.0 IU/mL	2	2000 IU/mL	LSP CAL	28	60	30
Apolipoprotein A-1 (APO A1)	1.3	75	10.0	14	2–8°C	S;Li Hep P	No	5.0	PEG-enhanced immunoturbidimetric	EPA	340, 694	15–200 mg/dL (0.15–2.00 g/L)	Males: 79–169 mg/dLFemales: 76–214 mg/dL (Males: 0.79–1.69 g/L Females:0.76–2.14 g/L)	2	400 mg/dL (4.00 g/L)	APO A1 & B CAL	28	60	14
Apolipoprotein B (APO B)	1.3	75	10.0	30	2–8°C	S;Li Hep P	No	5.0	PEG-enhanced immunoturbidimetric	EPA	340, 694	15–200 mg/dL (0.15–2.00 g/L)	Males: 46–174 mg/dLFemales:46–142 mg/dL (Males: 0.46–1.74g/L Females: 0.46–1.42g/L)	2	400 mg/dL (4.00 g/L)	APO A1 & B CAL	28	60	30
Aspartate Aminotransferase (AST)	1.8	425	10.0	90	2–8°C	S;Li Hep P	No	25.0	Modified IFCC	ENZ	340, 410	8–1000 U/L	<34 U/L	6	6000 U/L	ENZ 2 CAL	30	131	30
Aspartate Aminotransferase P5P (ASTPLc)	1.3	520	10.0	30†	2–8°C	S;Li Hep P	No	25.0	IFCC	ENZ	340, 410	8–1000 U/L	13–40 U/L	6	6000 U/L	ENZ 2 CAL	30	130	11
Calcium (CPC) (Ca (Serum/plasma))	1.3	445	8.0	30	15–25°C	S;Li Hep P	Yes	16.0	CPC	EPA	545, 658	1–15 mg/dL (0.25–3.75 mmol/L)	8.3–10.6 mg/dL (2.08–2.65 mmol/L)	2	30.0 mg/dL (7.50 mmol/L)	CHEM CAL	2	33	3
Calcium (CPC) (Ca (Urine))	1.3	445	8.0	30	15–25°C	Urine	Yes	16.0	CPC	EPA	545, 658	1–30 mg/dL (0.25–7.50 mmol/L)	100–300 mg/day (2.50–7.50 mmol/day)	2	60.0 mg/dL (15.00 mmol/L)	CHEM CAL	2	33	3
Calcium (Arsenazo) (CA_2 (Serum/plasma))	1.3	1025	3.0	63	15–25°C	S;Li Hep P	No	4.0	Arsenazo - Colorimetric	EPA	658, 694	1.0–16.0 mg/dL (0.25–4.00 mmol/L)	8.7–10.4 mg/dL (2.18–2.60 mmol/L)	2	1.0–32.0 mg/dL (0.25–8.00 mmol/L)	CHEM CAL	48 hrs	63	63

Assay (TDef name)	Test definition version	Test per well	Test Duration (min)	Reagent Onboard Well Stability (days)	Reagent Storage Temp	Sample Types	Reagent pack chimney	Sample Volume (µL)	Assay Reaction			Assay Ranges				Calibration			
									Assay Principle	Reaction Type	Wavelength (λ)	Assay Measuring Interval	Expected Values	Onboard Dilution Factor	Extended Range	Calibrator Name	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)
Calcium (Arsenazo) (CA_2 (Urine))	1.3	1025	3.0	63	15–25°C	Urine	No	4.0	Arsenazo - Colorimetric	EPA	658, 694	1.0–32.0 mg/dL (0.25–8.00 mmol/L)	100–300 mg/day (2.50–7.50 mmol/day)	2	1.0–160.0 mg/dL (0.25–40.00 mmol/L)	CHEM CAL	48 hrs	63	63
Carbamazepine (Carb)	1.3	100	8.0	30	2–8°C	S;Li Hep P	No	3.8	PETINIA	EPA	545, 694	0.4–20.0 µg/mL (1.7–84.7 µmol/L)	4.0–12.0 µg/mL (16.9–50.8 µmol/L)	2	0.4–40.0 µg/mL (1.7–169.3 µmol/L)	DRUG CAL II	30	30	7
Carbon Dioxide, Concentrated (CO2_c)	1.2	950	2.0	27	2–8°C	S;Li Hep P	No	5.7	Enzymatic	2PA	410, 478	10.0–40.0 mEq/L (10.0–40.0 mmol/L)	20.0–31.0 mEq/L (20.0–31.0 mmol/L)	—	—	CO2 CAL	30	30	6
Cholesterol_2 (Chol_2)	1.2	1050	10.0	26	2–8°C	S;Li Hep P	No	4.0	Colorimetric: cholesterol esterase and cholesterol oxidase conversion followed by a Trinder endpoint	EPA	505, 694	25–618 mg/dL (0.65–16.00 mmol/L)	Δ	2	1236 mg/dL (32.01 mmol/L)	CHEM CAL	2	50	7
Cholinesterase (CHE)	1.1	135	9.0	30†	2–8°C	S;Li Hep P	No	2.0	Butyrylthiocholine substrate	ENZ	410, 596	1,500–30,000 U/L	7000–19,000 U/L	2	1500–60,000 U/L	ENZ 1 CAL	30	120	7
Complement C3 (C3)	1.3	100	10.0	30	2–8°C	S	No	4.5	PEG-enhanced immunoturbidimetric	EPA	340, 694	0.5–500.0 mg/dL (0.01–5.00 g/L)	Δ	2.25	0.5–1125.0 mg/dL (0.01–11.25 g/L)	LSP CAL	28	60	14
Complement C4 (C4)	1.4	100	10.0	30	2–8°C	S	No	6.0	PEG-enhanced immunoturbidimetric	EPA	340, 694	0.4–140.0 mg/dL (0.01–1.40 g/L)	12.0–36.0 mg/dL (0.12–0.36 g/L)	3	0.4–420.0 mg/dL (0.01–4.20 g/L)	LSP CAL	28	60	14
C-Reactive Protein_2 (CRP_2)	1.3	250	8.0	30	2–8°C	S;Li Hep P	No	4.0	Latex-enhanced immunoturbidimetric	EPA	571	0.4–30.4 mg/dL (4–304 mg/L)	< 1.0 mg/dL (< 10 mg/L)	3	91.2 mg/dL (912 mg/L)	CRP_2 CAL	60	60	30
Creatine Kinase (CK_L)	1.1	166	10.0	29	2–8°C	S;Li Hep P	No	4.5	Enzymatic	ENZ	340, 596	15–1300 U/L	males is 46–171 U/L females is 34–145 U/L	6	7800 U/L	ENZ 3 CAL	30	202	21
Creatinine_2 (Crea_2 (serum/plasma))	1.4	736	8.0	17	15–25°C	S;Li Hep P	Yes	24.0	Jaffe, alkaline picrate, kinetic with blank rate correction	RRA	505, 571	0.15–30.00 mg/dL (13–2652 µmol/L)	Males 0.70–1.30 mg/dL Females 0.55–1.02 mg/dL (Males 62–115 µmol/LFemales 49–90 µmol/L)	2	60 mg/dL (5304 µmol/L)	CHEM CAL	2	180	6
Creatinine_2 (Crea_2 (urine))	1.4	736	8.0	17	15–25°C	Urine	Yes	24.0	Jaffe, alkaline picrate, kinetic with blank rate correction	RRA	505, 571	3.00–245.00 mg/dL (265–21658 µmol/L)	Males 950–2490 mg/day Female 600–1800 mg/day (Males 8.4–22.0 mmol/dayFemales 5.3–15.9 mmol/day)	3	735 mg/dL (64,975 µmol/L)	CHEM CAL	2	180	6

Assay (TDef name)	Test definition version	Test per well	Test Duration (min)	Reagent Onboard Well Stability (days)	Reagent Storage Temp	Sample Types	Reagent pack chimney	Sample Volume (µL)	Assay Reaction			Assay Ranges				Calibration			
									Assay Principle	Reaction Type	Wavelength (λ)	Assay Measuring Interval	Expected Values	Onboard Dilution Factor	Extended Range	Calibrator Name	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)
Cystatin C_2 (CYSC_2)	1.2	100	10.0	40	2–8°C	S;Li Hep P;K EDTA P	No	5.2	Latex-enhanced immunoturbidimetric	EPA	571, 805	0.25–8.93 mg/L	0.64–1.23 mg/L	3	0.25–26.79 mg/L	CYSC_2 CAL	60	61	40
Digoxin (Dgn)	1.3	200	10.0	30	2–8°C	S;Li Hep P	No	15.6	Latex-enhanced immunoturbidimetric	EPA	694	0.14–5.00 ng/mL (0.18–6.40 nmol/L)	0.80–2.00 ng/mL (1.02–2.56 nmol/L)	2	0.14–10.00 ng/mL (0.18–12.80 nmol/L)	TDM CAL	7	60	7
Direct Bilirubin 2 (DBil_2)	1.3	224	10.0	30	2–8°C	S;Li Hep P	No	14.3	Vanadate oxidation	EPA	451, 545	0.1–15.0 mg/dL (2–256 µmol/L)	≤ 0.3 mg/dL (≤ 5 µmol/L)	1.5	0.1–22.5 mg/dL (2–385 µmol/L)	CHEM CAL	8 hrs	60	30
Direct HDL Cholesterol (D_HDL)	1.3	224	8.0	89	2–8°C	S;Li Hep P	No	5.0	Elimination/catalase	2PA	596, 694	20.0–129.0 mg/dL (0.52–3.34 mmol/L)	Δ	2	258.0 mg/dL (6.68 mmol/L for)	HDL/LDL CAL	3	60	30
Enzymatic Creatinine_2 (ECre_2 (serum/plasma))	1.4	175	10.0	30	2–8°C	S;Li Hep P;K EDTA P	No	13.0	Enzymatic	EPA	596, 694	0.1–30.00 mg/dL (9–2652 µmol/L)	Δ	5	0.10–150 mg/dL (9–13,260 µmol/L)	CHEM CAL	2	180	30
Enzymatic Creatinine_2 (ECre_2 (urine))	1.4	175	10.0	30	2–8°C	Urine	No	13.0	Enzymatic	EPA	596, 694	1.0–245.00 mg/dL (Urine 88–21658 µmol/L)	Adult males Urine 800–2000 mg/day Adult females Urine 600–1800 mg/day	5	1.00–1225 mg/dL (88–108,290 µmol/L)	CHEM CAL	2	180	30
Enzymatic Hemoglobin A1c (A1c_E)	1.2	150	10.0	63	2–8°C	Whole blood;Hemolysate	No	4.5	Enzymatic	EPA	658, 805	3.80–14.00 %HbA1c (18.03–129.50 mmol/mol HbA1c)	< 5.7%: Normal 5.7–6.4%: Prediabetes ≥ 6.5%: Diabetic (< 39 mmol/mol: Normal 39–47 mmol/mol: Prediabetes ≥ 48 mmol/mol: Diabetic)	—	—	A1c_E CAL	11	180	63
Ethyl Alcohol (ETOH)	1.3	150	8.0	30	2–8°C	S;Li Hep P;Sodium Hep P;K EDTA P;Sodium fluoride/K oxalate P;Urine	No	8.0	Enzymatic reaction	RRA	340, 410	3.0–300.0 mg/dL (0.7–65.1 mmol/L)	Varied. Reportedly fatal 400.0 mg/mL (Varied. Reportedly fatal 86.8 mmol/L)	3	3.0–900.0 mg/dL (0.7–195.3 mmol/L)	TOX CAL	3	60	1
Fructosamine (Fruc)	1.1	100	10.0	30	2–8°C	S;Li Hep P;K EDTA P	No	16.0	Colorimetric end-point reaction	EPA	596, 694	30–1000 µmol/L	151–300 umol/L	—	—	Fruc CAL	28	180	30

Assay (TDef name)	Test definition version	Test per well	Test Duration (min)	Reagent Onboard Well Stability (days)	Reagent Storage Temp	Sample Types	Reagent pack chimney	Sample Volume (µL)	Assay Reaction			Assay Ranges				Calibration			
									Assay Principle	Reaction Type	Wavelength (λ)	Assay Measuring Interval	Expected Values	Onboard Dilution Factor	Extended Range	Calibrator Name	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)
Gamma-Glutamyl Transferase (GGT)	1.1	224	10.0	22	2–8°C	S;Li Hep P	No	10.0	Modified IFCC	ENZ	410, 478	7–1200 U/L	Adult males Serum/plasma: < 73 U/L Adult females Serum/plasma; < 38 U/L (Adult males Serum/plasma 73 U/LAdult females Serum/plasma 38 U/L)	3	7–3600 U/L	ENZ 1 CAL	30	60	22
Gentamicin (Gent)	1.4	100	8.0	30	2–8°C	S;Li Hep P	No	3.8	PETINIA	EPA	545, 694	0.5–12.0 µg/mL (1.1–25.9 µmol/L)	4.0–10.0 µg/mL (8.64–21.6 µmol/L)	2	0.5–24.0 µg/mL (1.1–51.8 µmol/L)	DRUG CAL II	30	30	7
Glucose Hexokinase_3 (serum/plasma) (GluH_3)	1.3	780	7.0	62	2–8°C	S;Li Hep P;K EDTA P;Sodium fluoride/K oxalate P	No	3.4	Hexokinase	EPA	340, 410	4–700 mg/dL (0.2–38.9 mmol/L)	Δ	3	2100 mg/dL (116.6 mmol/L)	CHEM CAL	2	182	30
Glucose Hexokinase_3 (urine) (GluH_3)	1.3	780	7.0	62	2–8°C	Urine	No	3.4	Hexokinase	EPA	340, 410	4–700 mg/dL (0.2–38.9 mmol/L)	Adults: < 0.5 g/day (2.8 mmol/day)	3	2100 mg/dL (116.6 mmol/L)	CHEM CAL	2	182	30
Glucose Hexokinase_3 (CSF) (GluH_3)	1.3	780	7.0	62	2–8°C	CSF	No	3.4	Hexokinase	EPA	340, 410	4–700 mg/dL (0.2–38.9 mmol/L)	Adult: 40–70 mg/dL Infant/child 60–80 mg/dL (Adult 2.2–3.9 mmol/LInfant/child3.3–4.4 mmol/L)	3	2100 mg/dL (116.6 mmol/L)	CHEM CAL	2	182	30
Glucose Oxidase (serum/plasma) (GluO)	1.3	700	10.0	51	2–8°C	S;Li Hep P	No	4.0	Glucose Oxidase Trinder	EPA	505, 694	6–750 mg/dL (0.3–41.6 mmol/L)	74–106 mg/dL (4.1–5.9 mmol/L)	2	1,500 mg/dL (83.3 mmol/L)	CHEM CAL	2	35	7
Glucose Oxidase (urine) (GluO)	1.3	700	10.0	51	2–8°C	Urine	No	4.0	Glucose Oxidase Trinder	EPA	505, 694	6–750 mg/dL (0.3–41.6 mmol/L)	Adults: < 0.5 g/day (Adults: < 0.5 g/day)	2	1,500 mg/dL (83.3 mmol/L)	CHEM CAL	2	35	7
Glucose Oxidase (CSF) (GluO)	1.3	700	10.0	51	2–8°C	CSF	No	4.0	Glucose Oxidase Trinder	EPA	505, 694	6–750 mg/dL (0.3–41.6 mmol/L)	Adult: 40–70 mg/dL Infants/children: 60–80 mg/dL (Adult .2–3.9 mmol/L Infants/children: 3.3–4.4 mmol/L)	2	1,500 mg/dL (83.3 mmol/L)	CHEM CAL	2	35	7
Haptoglobin (Hapt)	1.4	150	10.0	30†	2–8°C	S	No	3.4	PEG-enhanced immunoturbidimetric	EPA	340, 694	1–340 mg/dL (0.01–3.40 g/L)	40–280 mg/dL (0.40–2.80 g/L)	—	—	LSP CAL	28	30	30

Assay (TDef name)	Test definition version	Test per well	Test Duration (min)	Reagent Onboard Well Stability (days)	Reagent Storage Temp	Sample Types	Reagent pack chimney	Sample Volume (µL)	Assay Reaction			Assay Ranges				Calibration			
									Assay Principle	Reaction Type	Wavelength (λ)	Assay Measuring Interval	Expected Values	Onboard Dilution Factor	Extended Range	Calibrator Name	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)
High Sensitivity C-Reactive Protein (hsCRP)	1.2	185	8.0	30	2–8°C	S;Li Hep P;K EDTA P	No	10.0	Latex-enhanced immunoturbidimetric	EPA	571, 658	0.16–10.0 mg/L	Δ	20	200 mg/L	hsCRP CAL	60	60	30
Immunoglobulin A_2 (IgA_2)	1.3	75	10.0	30	2–8°C	S;Li Hep P	No	4.0	PEG-enhanced immunoturbidimetric	EPA	340, 596	33.0–540.0 mg/dL (0.33–5.40 g/L)	40.0–350.0 mg/dL (0.40–3.50 g/L)	10	15.0–5,400.0 mg/dL (0.15–54.00 g/L)	LSP CAL	28	60	30
Immunoglobulin G_2 (IgG_2)	1.3	90	10.0	30	2–8°C	S;Li Hep P	No	2.0	PEG-enhanced immunoturbidimetric	EPA	340, 694	140–3400 mg/dL (1.40–34.00 g/L)	650–1,600 mg/dL (6.50–16.00 g/L)	10	70–34,000 mg/dL (0.70–340.00 g/L)	LSP CAL	28	60	30
Immunoglobulin M_2 (IgM_2)	1.3	90	10.0	30	2–8°C	S;Li Hep P;K EDTA P	No	9.0	PEG-enhanced immunoturbidimetric	EPA	340, 694	21.0–330.0 mg/dL (0.21–3.30 g/L)	50.0–300.0 mg/dL (0.50–3.00 g/L)	10	8.0–3,300.0 mg/dL (0.08–33.00 g/L)	LSP CAL	28	60	30
Inorganic Phosphorus (IP (serum/plasma))	1.4	850	10.0	30	15–25°C	S;Li Hep P	No	8.0	Phosphomolybdate	EPA	340, 658	0.3–20 mg/dL (0.10–6.46 mmol/L)	Adult 2.4–5.1 mg/dL (Adult 0.78–1.65 mmol/L)	2	0.3–40.0 mg/dL (0.1–12.92 mmol/L)	CHEM CAL	2	180	7
Inorganic Phosphorus (IP (urine))	1.4	850	10.0	30	15–25°C	Urine	No	8.0	Phosphomolybdate	EPA	340, 658	4–100 mg/dL (1.29–32.30 mmol/L)	0.4–1.3 g/day for adults on an unrestricted diet (12.9–42.0 mmol/day for adults on an unrestricted diet)	2.6	4.0–260 mg/dL (1.29–83.98 mmol/L)	CHEM CAL	2	180	7
Iron_2 (Iron_2)	1.3	224	10.0	30	2–8°C	S;Li Hep P	No	25.0	Ferrozine	EPA	571, 658	2–1000 µg/dL (0.4–179.0 µmol/L)	Male serum 65–175 µg/dL Female serum 50–170 µg/dL (Male serum 11.6–31.3 µmol/L Female serum 9.0–30.4 µmol/L)	2	2000 µg/dL (358.0 µmol/L)	CHEM CAL	2	180	30
Lactate (Lac)	1.3	95	4.0	30†	2–8°C	Li Hep P K EDTA P;Sodium fluoride/ K oxalate P;	No	4.0	Lactate oxidase to pyruvate and hydrogen peroxide	EPA	545, 694	0.6–110.0 mg/dL (0.07–12.21 mmol/L)	4.5–19.8 mg/dL (0.50–2.20 mmol/L)	—	—	SPCL CHEM CAL	7	62	30

Assay (TDef name)	Test definition version	Test per well	Test Duration (min)	Reagent Onboard Well Stability (days)	Reagent Storage Temp	Sample Types	Reagent pack chimney	Sample Volume (µL)	Assay Reaction			Assay Ranges				Calibration			
									Assay Principle	Reaction Type	Wavelength (λ)	Assay Measuring Interval	Expected Values	Onboard Dilution Factor	Extended Range	Calibrator Name	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)
Lactate_2 (Lac_2)	1.1	95	4.0	30†	2–8°C	;Li Hep P; K EDTA Plasma; Sodium fluoride/K oxalate Plasma	No	4.0	Lactate oxidase to pyruvate and hydrogen peroxide	EPA	545, 694	0.6–110.0 mg/dL (0.07–12.21 mmol/L)	4.5–19.8 mg/dL (0.50–2.20 mmol/L)	10	0.6–1100.0 mg/dL (0.07–122. 10 mmol/L)	SPCL CHEM CAL	7	62	30
Lactate_2 CSF (Lac_2)	1.1	95	4.0	30†	2–8°C	CSF	No	4.0	Lactate oxidase to pyruvate and hydrogen peroxide	EPA	545, 694	0.9–70 mg/dL (0.10–7.77 mmol/L)	5.4–19.8 mg/dL (0.60–2.20 mmol/L)	2	0.9–140 mg/dL (0.10–15.5 4 mmol/L)	SPCL CHEM CAL	7	62	30
Lactate Dehydrogenase L-P (LDLP)	1.8	224	9.0	28	2–8°C	S;Li Hep P	No	14.0	Lactate / NAD	ENZ	340, 410	14–750 U/L	120–246 U/L	6	14–4500 U/L	ENZ 1 CAL	30	60	28
LDL Cholesterol Direct (DLDL)	1.2	200	10.0	15	2–8°C	S;Li Hep P	No	5.0	Elimination/catalase	EPA	596, 694	5.0–1000.0 mg/dL (0.13–25.90 mmol/L)	Δ	—	—	HDL/LDL CAL	3	121	15
Lidocaine (LIDO)	1.3	100	8.0	31	2–8°C	S;Sodium Hep P;K EDTA P	No	7.5	PETINIA	EPA	545, 694	0.5–12.0 µg/mL (2.1–51.2 µmol/L)	1.5–5.0 µg/mL (6.4–21.3 µmol/L)	2	0.5–24.0 µg/mL (2.1–102.5 µmol/L)	DRUG CAL II	30	61	18
Lipase (Lip)	1.2	160	8.0	9	2–8°C	S;Li Hep P	No	3.0	Colorimetric rate	ENZ	571, 694	8–700 U/L	12–53 U/L	5	9–3500 U/L	ENZ 1 CAL	30	61	9
Lipoprotein (Lp(a))	1.3	100	10.0	30	2–8°C	S;Li Hep P	No	9.0	Latex-enhanced immunoturbidimetric	EPA	694	10.00–85.00 mg/dL (0.100–0.850 g/L)	30.00 mg/dL (0.300 g/L)	—	—	Lp(a) CAL	14	60	30
Lithium (Li)	1.1	100	10.0	13	2–8°C	S;Sodium Hep P;K EDTA P	Yes	13.0	Colorimetric endpoint chemistry	EPA	505, 694	0.10–3.00 mmol/L	1.00–1.20 mmol/L	2	0.10–6.00 mmol/L	CHEM CAL	2	63	4

Assay (TDef name)	Test definition version	Test per well	Test Duration (min)	Reagent Onboard Well Stability (days)	Reagent Storage Temp	Sample Types	Reagent pack chimney	Sample Volume (µL)	Assay Reaction			Assay Ranges				Calibration			
									Assay Principle	Reaction Type	Wavelength (λ)	Assay Measuring Interval	Expected Values	Onboard Dilution Factor	Extended Range	Calibrator Name	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)
Lithium_2 (LITH_2)	1.0	100	10.0	52	2–8°C	S;Sodium Hep P;K EDTA P	Yes	13.0	Colorimetric endpoint chemistry	EPA	505, 694	0.10–3.00 mmol/L	1.00–1.20 mmol/L	2	0.10–6.00 mmol/L	CHEM CAL	2	108	14
Magnesium (Mg (serum/plasma))	1.3	200	8.0	14	2–8°C	S;Li Hep P	Yes	12.0	Xylidyl Blue	EPA	505, 694	0.50–5.00 mg/dL (0.21–2.06 mmol/L)	Adult 1.60–2.60 mg/dL (Adult 0.66–1.07 mmol/L)	2	10.00 mg/dL (4.11 mmol/L)	CHEM CAL	2	180	3
Magnesium (Mg (urine))	1.3	200	8.0	14	2–8°C	Urine	Yes	12.0	Xylidyl Blue	EPA	505, 694	Urine 1.00–14.00 mg/dL (0.41–5.75 mmol/L)	Adult 24–255 mg/24 hours (Adult 0.99–10.45 mmol/24 hours)	2	28.00 mg/dL (11.51 mmol/L)	CHEM CAL	2	180	3
Microalbumin_2 (µALB_2)	1.4	105	10.0	30	2–8°C	Urine	Yes	13.7	PEG-enhanced immunoturbidimetric	EPA	340, 596	0.3–38.0 mg/dL (3–380 mg/L)	30 mg/day for adults	10	380 mg/dL (3800 mg/L)	µALB_2 CAL	60	180	30
Mycophenolic Acid (MPA) [OUS]	1.2	150	9.0	33	2–8°C	;Li Hep P K EDTA P;	No	5.7	EMIT	RRA	340, 410	0.10–15.00 µg/mL	No established therapeutic range exists for mycophenolic acid in plasma.	—	0.10–30.00 µg/mL	Emit 2000 Myco-phenolic Acid Calibrators (0, 0.5, 2, 5, 10, 15 µg/mL)	—	63	6
N-Acetylprocainamide (NAPA)	1.3	100	7.0	31	2–8°C	S;Li Hep P;Sodium Hep P K EDTA P;	No	2.5	PETINIA	EPA	545, 694	0.5–30.0 µg/mL (1.8–108.3 µmol/L)	The combined procainamide and N-acetylprocainamide therapeutic range is 10–30 µg/mL.	2	0.5–60.0 µg/mL (1.8–216.6 µmol/L)	DRUG CAL II	30	61	12
Pancreatic Amylase (PAmy)	1.2	215	9.0	30	2–8°C	S	No	16.0	Antibody-blocked colorimetric amylase	ENZ	410, 694	5–1500 U/L	13–53 U/L	5	5–7,500 U/L	—	—	—	1
Pancreatic Amylase_2 (serum) (Pamy_2) [OUS]	1.2	215	9.0	31	2–8°C	S	No	16.0	Enzymatic reaction	ENZ	410, 694	20–1500 U/L	Serum and Plasma: 13–53 U/L	5	20–7500 U/L	SPCL CHEM CAL	7	62	31
Pancreatic Amylase_2 (urine) (Pamy_2) [OUS]	1.2	215	9.0	31	2–8°C	Urine	No	16.0	Enzymatic reaction	ENZ	410, 694	20–1500 U/L	Urine: Spontaneously voided urine: Male 7–356 U/L Female 13–319 U/L	5	20–7500 U/L	SPCL CHEM CAL	7	62	31
Phenobarbital (Phnb)	1.3	100	8.0	30	2–8°C	S;Li Hep P	No	5.0	PETINIA	EPA	545, 694	3.0–80.0 µg/mL (12.9–344.8 µmol/L)	15.0–40.0 µg/mL (64.7–172.4 µmol/L)	2	3.0–160.0 µg/mL (12.9–689.6 µmol/L)	DRUG CAL	90	30	7
Phenytoin (Phny)	1.4	100	8.0	30	2–8°C	S;Li Hep P	No	5.0	PETINIA	EPA	545, 694	2.0–40.0 µg/mL (7.9–158.4 µmol/L)	10.0–20.0 µg/mL (39.6–79.2 µmol/L)	—	2.0–80.0 µg/mL (7.9–316.8 µmol/L)	DRUG CAL	90	28	7

Assay (TDef name)	Test definition version	Test per well	Test Duration (min)	Reagent Onboard Well Stability (days)	Reagent Storage Temp	Sample Types	Reagent pack chimney	Sample Volume (µL)	Assay Reaction			Assay Ranges				Calibration			
									Assay Principle	Reaction Type	Wavelength (λ)	Assay Measuring Interval	Expected Values	Onboard Dilution Factor	Extended Range	Calibrator Name	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)
Prealbumin (PreAlb)	1.3	100	10.0	30	2–8°C	S	No	7.5	PEG-enhanced immunoturbidimetric	EPA	340	5.0–70.0 mg/dL (50–700 mg/L)	10.0–40.0 mg/dL (100–400 mg/L)	2	140.0 mg/dL (1,400 mg/L)	LSP CAL	28	60	7
Procainamide (PROC)	1.3	100	7.0	31	2–8°C	S;Li Hep P;Sodium Hep P K EDTA P;	No	2.5	PETINIA	EPA	545, 694	0.5–20.0 µg/mL (2.1–85.0 µmol/L)	4.0–12.0 µg/mL (17.0–51.0 µmol/L)	2	0.5–40.0 µg/mL (2.1–170.0 µmol/L)	DRUG CAL II	30	61	18
Rheumatoid Factor (RF)	1.4	90	10.0	21	2–8°C	S	No	11.5	Latex-enhanced immunoturbidimetric	EPA	571, 805	3.5–90.0 IU/mL	< 14 IU/mL	10	900 IU/mL	LSP CAL	28	60	14
Salicylate (Sal)	1.3	150	10.0	30	2–8°C	S;Li Hep P	No	8.0	Colorimetric	EPA	340, 410	3.0–100.0 mg/dL (0.22–7.20 mmol/L)	Toxic >30 mg/dL	4	3.0–400.0 mg/dL (0.22–28.8 mmol/L)	TOX CAL	3	180	21
Tacrolimus (TACR)	1.2	100	6.0	31	2–8°C	K EDTA Whole blood	No	25.0	EMIT	RRA	340	2.0–30.0 ng/mL	No firm therapeutic range exists for tacrolimus in whole blood.	—	2.0–80.0 ng/mL	Emit 2000 Tacrolimus Calibrators (0, 2.5, 5, 10, 20, 30 ng/mL)	56	64	10
Theophylline (Theo)	1.3	100	6.0	30	2–8°C	S;Li Hep P	No	5.0	PETINIA	EPA	545, 694	2.0–40.0 µg/mL (11.1–222.0 µmol/L)	10–20 µg/mL (56–111 µmol/L)	2	2.0–80.0 µg/mL (11.1–444.0 µmol/L)	DRUG CAL	90	30	7
Tobramycin (Tob)	1.4	100	9.0	30	2–8°C	S;Li Hep P	No	3.8	PETINIA	EPA	545, 694	0.3–12.0 µg/mL (0.6–25.7 µmol/L)	4–10 µg/mL (8.6–21.4 µmol/L)	2	0.3–24.0 µg/mL (0.6–51.4 µmol/L)	DRUG CAL II	30	30	7
Total Bilirubin_2 (TBil_2)	1.4	224	10.0	30	2–30°C	S;Li Hep P	No	14.3	Vanadate oxidation	EPA	451, 545	0.15–35.0 mg/dL (3–599 µmol/L)	Δ	2	70.0 mg/dL (1197 µmol/L)	CHEM CAL	8 hrs	60	30
Total Iron Binding Capacity (TIBC)	1.3	100	10.0	7	2–8°C	S	Yes	24.0	Sequential release and uptake of iron	EPA	658	40–670 µg/dL (7.16–119.93 µmol/L)	250–425 µg/dL (44.75–76.08 µmol/L)	—	—	SPCL CHEM CAL	7	180	7
Total Protein II (TP)	1.7	925	10.0	90	15–25°C	S;Li Hep P	Yes	17.5	Biuret	EPA	545	2.0–12.0 g/dL (20–120 g/L)	5.7–8.2 g/dL (57–82 g/L)	2	24.0 g/dL (240 g/L)	CHEM CAL	2	181	30
Total Protein, CSF/Urine (UCFP)	1.1	185	5.0	30	2–8°C	Urine; CSF	Yes	6.3	Pyrogallol red-molybdate	EPA	596, 694	6.0–250.0 mg/dL (60–2500 mg/L)	Urine: 1–14 mg/dL CSF: 15–45 mg/dL (Urine:10–140 mg/L CSF: 150–450 mg/L)	10	6.0–2500 mg/dL (60–25,000 mg/L)	UCFP CAL	60	60	7

Assay (TDef name)	Test definition version	Test per well	Test Duration (min)	Reagent Onboard Well Stability (days)	Reagent Storage Temp	Sample Types	Reagent pack chimney	Sample Volume (µL)	Assay Reaction			Assay Ranges				Calibration			
									Assay Principle	Reaction Type	Wavelength (λ)	Assay Measuring Interval	Expected Values	Onboard Dilution Factor	Extended Range	Calibrator Name	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)
Total Protein_2 (Upro)	1.4	200	10.0	30	15–25°C	Urine; CSF	Yes	13.3	Dye binding	EPA	596, 694	1.0–125.0 mg/dL (10–1250 mg/L)	Δ	4	1.0–500.0 mg/dL (10–5000 mg/L)	UPro CAL	21	60	30
Transferrin (Trf)	1.3	110	10.0	30	2–8°C	S;Li Hep P;K EDTA P	No	2.0	PEG-enhanced immunoturbidimetric	EPA	340, 596	1–440 mg/dL (0.01–4.40 g/L)	Males Serum/Plasma 215–365 mg/dLFemales Serum/Plasma 250–380 mg/dL (Males Serum/Plasma 2.15–3.65 g/LFemales Serum/Plasma 2.50–3.80 g/L)	10	4400 mg/dL (44.00 g/L)	LSP CAL	28	60	14
Triglycerides (Trig)	1.2	250	4.0	30	2–8°C	S;Li Hep P;K EDTA P	No	4.0	GPO	EPA	505, 694	10–550 mg/dL (0.11–6.22 mmol/L)	Δ	2	1100 mg/dL (12.43 mmol/L)	CHEM CAL	2	60	14
Urea Nitrogen (UN_c (serum/plasma))	1.9	780	7.0	90	2–8°C	S;Li Hep P	No	7.0	Urease with GLDH	RRA	340, 410	5–150 mg/dL (1.8–53.6 mmol/L)	Adult 9–23 mg/dL (Adult 3.2–8.2 mmol/L)	2	300 mg/dL (107.1 mmol/L)	CHEM CAL	2	75	6
Urea Nitrogen (UN_c (urine))	1.9	780	7.0	90	2–8°C	Urine	No	7.0	Urease with GLDH	RRA	340, 410	35–1000 mg/dL (12.5–357.0 mmol/L)	Adult 12–20 g/day (Adult 0.43–0.71 mol/day)	2	2000 mg/dL (714 mmol/L)	CHEM CAL	2	75	6
Uric Acid (UA (serum))	1.3	600	7.0	30	2–8°C	S	No	11.0	Uricase/Peroxidase	EPA	545, 694	0.5–20 mg/dL (30–1190 µmol/L)	Male Serum/Plasma 3.7–9.2 mg/dLFemale Serum/Plasma 3.1–7.8 mg/dL (Male Serum/Plasma 220–547 µmol/LFemale Serum/Plasma 184–464 µmol/L)	5	100.0 mg/dL (5950 µmol/L)	CHEM CAL	2	183	7
Uric Acid (UA (urine))	1.3	600	7.0	30	2–8°C	Urine	No	11.0	Uricase/Peroxidase	EPA	545, 694	0.9–180 mg/dL (54–10710 µmol/L)	250–750 mg/day (1.48–4.43 mmol/day)	2	360.0 mg/dL (21420 µmol/L)	CHEM CAL	2	183	7
Valproic Acid (VPA)	1.4	100	8.0	30	2–8°C	S;Li Hep P	No	2.5	PETINIA	EPA	545, 694	3.0–150.0 µg/mL (20.8–1040.1 µmol/L)	50–100 µg/mL (346–693 µmol/L)	2	3.0–300.0 µg/mL (20.8–2080.2 µmol/L)	DRUG CAL II	30	30	7
Vancomycin (Vanc)	1.4	100	9.0	30	2–8°C	S;Li Hep P	No	2.5	PETINIA	EPA	545, 694	3.0–50.0 µg/mL (2.1–34.5 µmol/L)	Peak 18–26 µg/mLTrough 5–10 µg/mL (Peak 12.4–17.9 µmol/LTrough 3.5–6.9 µmol/L)	2	3.0–100.0 µg/mL (2.1–69.0 µmol/L)	DRUG CAL II	30	30	7

Assay (TDef name)	Test definition version	Test per well	Test Duration (min)	Reagent Onboard Well Stability (days)	Reagent Storage Temp	Sample Types	Reagent pack chimney	Sample Volume (µL)	Assay Reaction			Assay Ranges				Calibration			
									Assay Principle	Reaction Type	Wavelength (λ)	Assay Measuring Interval	Expected Values	Onboard Dilution Factor	Extended Range	Calibrator Name	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)
Wide-Range C-Reactive Protein (wrCRP) [OUS]	1.3	250	8.0	51	2–8°C	S;Li Hep P	No	10.0	Latex-enhanced immunoturbidimetric	EPA	571	0.050–15.600 mg/dL (0.50–156.00 mg/L)	0.000–0.500 mg/dL (0.00–5.00 mg/L)	4	0.050–62.400 mg/dL (0.50–624.00 mg/L)	wrCRP CAL	28	61	51
β2-Microglobulin (B2M)	1.3	100	8.0	30	2–8°C	S;Li Hep P;K EDTA P	No	5.0	Latex-enhanced immunoturbidimetric	EPA	545	0.25–18.00 mg/L	1.00–2.40 mg/L	5	90.00 mg/L	B2M CAL	30	60	21

Drugs of Abuse Technical Assay Summary

This document applies to system software version 1.24. Assay availability is dependent on regulatory status in each country.

The Instructions For Use (IFU) is the primary source for assay details and should always be consulted for the most up-to-date information.

Assay [TDEF Name]	Abbreviation Product/Test Name	Tdef Version	Test per well	Test Duration (min)	Well Stability (days)	Sample Volume µL	Reaction Type	Wavelength (λ)	Qualitative Cutoff (Semiquantitative interval)	Level 0††	Level 1	Level 2	Level 3	Level 4	Level 5	Drug Used	Lot Calibration Interval (days)	Pack Calibration Interval (days)
										10445406 (9A509UL)	10445407 (9A529UL)	10445408 (9A549UL)	10445409 (9A569UL)	10445410 (9A589UL)	10445411 (9A609UL)			
Amphetamines (Amp)	Amp300	1.3	190	7	30	13.5	RRA	340, 410	300 ng/mL (100–1000 ng/mL)	0	300	500	1000	—	—	D-Methamphetamine	60	20
Amphetamines (Amp)	Amp500	1.4	190	7	30	8.0	RRA	340, 410	500 ng/mL (150–1800 ng/mL)	0	300	500	1000	—	2000	D-Methamphetamine	60	20
Amphetamines (Amp)	Amp1K	1.4	190	7	30	5.0	RRA	340, 410	1000 ng/mL (150–1800 ng/mL)	0	300	500	1000	—	2000	D-Methamphetamine	60	20
Barbiturates (Brb)	Brb200	1.3	190	7	30	17.5	RRA	340, 410	200 ng/mL (40–750 ng/mL)	0	—	100	200	300	800	Secobarbital	60	30
Barbiturates (Brb)	Brb300	1.3	190	7	30	17.5	RRA	340, 410	300 ng/mL (40–750 ng/mL)	0	—	100	200	300	800	Secobarbital	60	30
Benzodiazepines (Bnz)	Bnz200	1.3	190	7	30	17.5	RRA	340, 410	200 ng/mL (50–900 ng/mL)	0	—	100	200	300	1000	Lormetazepam	60	20
Benzodiazepines (Bnz)	Bnz300	1.3	190	7	30	17.5	RRA	340, 410	300 ng/mL (50–900 ng/mL)	0	—	100	200	300	1000	Lormetazepam	60	20
Cannabinoids THC (Thc)	Thc 20	1.3	190	7	30	25.0	RRA	340, 410	20 ng/mL (10–55 ng/mL)	0	—	20	50	100	—	11-nor- Δ9-THC-9-COOH	60	5
Cannabinoids THC (Thc)	Thc 50	1.3	190	7	30	13.0	RRA	340, 410	50 ng/mL (15–180 ng/mL)	0	—	20	50	100	200	11-nor- Δ9-THC-9-COOH	60	5
Cannabinoids THC (Thc)	Thc 100	1.3	190	7	30	9.5	RRA	340, 410	100 ng/mL (15–180 ng/mL)	0	—	—	50	100	200	11-nor- Δ9-THC-9-COOH	60	5
Cocaine Metabolite (Coc)	Coc150	1.5	190	7	30	25.0	RRA	340, 410	150 ng/mL (36–900 ng/mL)	0	—	150	300	500	1000	Benzoylecgonine	40	20
Cocaine Metabolite (Coc)	Coc300	1.5	190	7	30	25.0	RRA	340, 410	300 ng/mL (36–900 ng/mL)	0	—	150	300	500	1000	Benzoylecgonine	40	20
Methadone (Mdn150)	Mdn150	1.5	190	7	30	23.0	RRA	340, 410	150 ng/mL (40–450 ng/mL)	0	—	150	300	500	—	Methadone	60	20
Methadone (Mdn300)	Mdn300	1.5	190	7	30	11.5	RRA	340, 410	300 ng/mL (90–900 ng/mL)	0	—	—	300	500	1000	Methadone	60	20
Opiates (Op)	Op300	1.3	190	7	30	24.0	RRA	340, 410	300 ng/mL (75–1800 ng/mL)	0	300	1000	2000	—	—	Morphine	60	30
Opiates (Op)	Op2000	1.3	190	7	30	6.0	RRA	340, 410	2000 ng/mL (320–3800 ng/mL)	0	—	1000	2000	—	4000	Morphine	60	30
Phencyclidine (Pcp25)	Pcp25	1.3	190	7	30	23.5	RRA	340, 410	25 ng/mL (5–75 ng/mL)	0	—	12.5	25	75	—	Phencyclidine	60	19
Ecstasy (Xtc300)	Xtc300	1.5	50	7	30	23.0	RRA	340, 410	300 ng/mL (75–500 ng/mL)	0	150	300	500	—	—	methylenedioxymethamphetamine (MDMA)	60	15

Assay [TDEF Name]	Abbreviation Product/Test Name	Tdef Version	Test per well	Test Duration (min)	Well Stability (days)	Sample Volume µL	Reaction Type	Wavelength (λ)	Qualitative Cutoff (Semiquantitative interval)	Level 0††	Level 1	Level 2	Level 3	Level 4	Level 5	Drug Used	Lot Calibration Interval (days)	Pack Calibration Interval (days)
Ecstasy (Xtc500)	Xtc500	1.6	50	7	30	16.0	RRA	340, 410	500 ng/mL (75–1000 ng/mL)	0	150	300	500	1000	—	methylenedioxymethamphetamine (MDMA)	60	15

Assay [TDEF Name]	Abbreviation Product/Test Name	Tdef Version	Test per well	Test Duration (min)	Well Stability (days)	Sample Volume µL	Reaction Type	Wavelength (λ)	Qualitative Cutoff (Semiquantitative interval)	Level 0††	Level 1	Level 2	Level 3	Level 4	Level 5	Drug Used	Lot Calibration Interval (days)	Pack Calibration Interval (days)
										—	11099437	—	—	—	—			
Methadone Metabolite EDDP (MetMtb)	MetMtb	1.3	250	7	30	25.0	RRA	340, 410	1000 ng/mL	—	1000	—	—	—	—	2-ethylidine-1.5-dimethyl-3.3-diphenylpyrrolidine (EDDP)	60	14

Assay [TDEF Name]	Abbreviation Product/Test Name	Tdef Version	Test per well	Test Duration (min)	Well Stability (days)	Sample Volume µL	Reaction Type	Wavelength (λ)	Qualitative Cutoff (Semiquantitative interval)	Level 0††	Level 1	Level 2	Level 3	Level 4	Level 5	Drug Used	Lot Calibration Interval (days)	Pack Calibration Interval (days)
										10445406 (9A509UL)	10720807 (9T529UL)	10720813 (9T549UL)	10720814 (9T569UL)	10720815 (9T589UL)	—			
Oxycodone (OXY)	OXY100	1.2	190	7	40	12.0	RRA	340	100 ng/mL (50–400 ng/mL)	0	100	300	500	—	—	Oxycodone	62	28
Oxycodone (OXY)	OXY300	1.2	190	7	40	4.0	RRA	340	300 ng/mL (75–1000 ng/mL)	0	100	300	500	1000	—	Oxycodone	62	28

Calibrator Summary

This document applies to system software version 1.24. Assay availability is dependent on regulatory status in each country.

The Instructions For Use (IFU) is the primary source for assay details and should always be consulted for the most up-to-date information.

Calibrator Name	Calibrator SMN	Assay	Tdef Name	Assay SMN	Onboard Storage Available	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)	C0 Adjust Pack Cal	Levels used in Lot Calibration	Calibrator Unopened Storage Temp	Calibrator Format (Lyophilized/Liquid)	Calibrator Volume (mL)
CH A1c_E CAL	11099338	Enzymatic Hemoglobin A1c	A1c_E	11097536	No	11	180	63	—	3	2–8°C	Lyophilized	5.0
CH AlbP CAL	11099310	Albumin BCP	AlbP	11097530	Yes	8 hrs	30	8	—	2	2–8°C	Lyophilized	2.0
CH ALP_2 CAL	11099316	Alkaline Phosphatase, Concentrated	ALP_2c	11097600	Yes	30	60	17	—	2	2–8°C	Liquid	1.0
CH APO A1 & B CAL	11099329	Apolipoprotein A-1	APO A1	11097625	No	28	60	14	—	5	2–8°C	Lyophilized	1.0
		Apolipoprotein B	APO B	11097626	No	28	60	30	—	5	2–8°C	Lyophilized	1.0
CH B2M CAL	11099442	β2-Microglobulin	B2M	11097635	Yes	30	60	21	—	2	2–8°C	Lyophilized	1.0
CH CHEM CAL	11099411	Albumin BCG	Alb	11097590	Yes	2	97	60	—	2	2–8°C	Lyophilized	3.0
		Calcium (Arsenazo)	CA_2	11097644	Yes	48 hrs	63	63	—	2	2–8°C	Lyophilized	3.0
		Calcium (CPC)	Ca	11097595	Yes	2	33	3	—	2	2–8°C	Lyophilized	3.0
		Cholesterol_2	Chol_2	11097609	Yes	2	50	7	C0ADJUST	2	2–8°C	Lyophilized	3.0
		Creatinine_2	Crea_2	11097596	Yes	2	180	6	—	2	2–8°C	Lyophilized	3.0
		Direct Bilirubin 2	DBil_2	11097532	Yes	8 hrs	60	30	—	2	2–8°C	Lyophilized	3.0
		Enzymatic Creatinine_2	ECre_2	11097533	Yes	2	180	30	—	2	2–8°C	Lyophilized	3.0
		Glucose Hexokinase_3	GluH_3	11097592	Yes	2	182	30	—	2	2–8°C	Lyophilized	3.0
		Glucose Oxidase	GluO	11097621	Yes	2	35	7	C0ADJUST	2	2–8°C	Lyophilized	3.0
		Inorganic Phosphorus	IP	11097611	Yes	2	180	7	C0ADJUST	2	2–8°C	Lyophilized	3.0
		Iron_2	Iron_2	11097601	Yes	2	180	30	—	2	2–8°C	Lyophilized	3.0
		Lithium	Li	11097535	Yes	2	63	4	—	2	2–8°C	Lyophilized	3.0
		Lithium_2	LITH_2	11532401	Yes	2	108	14	—	2	2–8°C	Lyophilized	3.0
		Magnesium	Mg	11097612	Yes	2	180	3	—	2	2–8°C	Lyophilized	3.0
		Total Bilirubin_2	TBil_2	11097531	Yes	8 hrs	60	30	—	2	2–8°C	Lyophilized	3.0
		Total Protein II	TP	11097604	Yes	2	181	30	—	2	2–8°C	Lyophilized	3.0

Calibrator Name	Calibrator SMN	Assay	Tdef Name	Assay SMN	Onboard Storage Available	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)	C0 Adjust Pack Cal	Levels used in Lot Calibration	Calibrator Unopened Storage Temp	Calibrator Format (Lyophilized/Liquid)	Calibrator Volume (mL)
CH CHEM CAL	11099411	Triglycerides (concentrated)	Trig	11097591	Yes	2	60	14	C0ADJUST	2	2–8°C	Lyophilized	3.0
		Urea Nitrogen	UN_c	11097593	Yes	2	75	6	C0ADJUST	2	2–8°C	Lyophilized	3.0
		Uric Acid	UA	11097608	Yes	2	183	7	C0ADJUST	2	2–8°C	Lyophilized	3.0
CH CHEM III CAL	11099335	Ammonia	Amm	11097529	Yes	30	30	3	—	3	2–8°C	Liquid	2.5
CH CO2 CAL	11099401	Carbon Dioxide, Concentrated	CO2_c	11097521	Yes	30	30	6	—	2	2–8°C	Liquid	21.0
CH CRP_2 CAL	11099430	C-Reactive Protein_2	CRP_2	11097631	Yes	60	60	30	—	6	2–8°C	Liquid	1.0
CH DRUG CAL	11099336	Phenobarbital	Phnb	11097514	No	90	30	7	—	5	2–8°C	Liquid	3.0
		Phenytoin	Phny	11097510	No	90	28	7	—	5	2–8°C	Liquid	3.0
		Theophylline	Theo	11097513	No	90	30	7	—	5	2–8°C	Liquid	3.0
CH DRUG CAL II	11099405	Carbamazepine	Carb	11097515	Yes	30	30	7	—	5	2–8°C	Liquid	5.0
		Lidocaine	LIDO	11097539	Yes	30	61	18	—	5	2–8°C	Liquid	5.0
		N-Acetylprocainamide	NAPA	11097537	Yes	30	61	12	—	5	2–8°C	Liquid	5.0
		Procainamide	PROC	11097538	Yes	30	61	18	—	5	2–8°C	Liquid	5.0
		Tobramycin	Tob	11097517	Yes	30	30	7	—	5	2–8°C	Liquid	5.0
		Gentamicin	Gent	11097516	Yes	30	30	7	—	5	2–8°C	Liquid	5.0
		Valproic Acid	VPA	11097512	Yes	30	30	7	—	5	2–8°C	Liquid	5.0
		Vancomycin	Vanc	11097511	Yes	30	30	7	—	5	2–8°C	Liquid	5.0
CH ENZ 1 CAL	11099317	Cholinesterase	CHE	11097615	Yes	30	120	7	—	2	2–8°C	Liquid	2.5
		Gamma-Glutamyl Transferase	GGT	11097597	Yes	30	60	22	—	2	2–8°C	Liquid	2.5
		Lactate Dehydrogenase L-P	LDLP	11097594	Yes	30	60	28	—	2	2–8°C	Liquid	2.5
		Lipase	Lip	11097606	Yes	30	61	9	—	2	2–8°C	Liquid	2.5
		Alanine Aminotransferase	ALT	11097605	Yes	30	131	30	—	2	2–8°C	Liquid	1.5
CH ENZ 2 CAL	11099318	Alanine Aminotransferase P5P	ALTPLc	11097638	Yes	30	130	4	—	0	2–8°C	Liquid	1.5
		Aspartate Aminotransferase	AST	11097607	Yes	30	131	30	—	2	2–8°C	Liquid	1.5
CH ENZ 2 CAL	11099318	Aspartate Aminotransferase P5P	ASTPLc	11097639	Yes	30	130	11	—	0	2–8°C	Liquid	1.5

Calibrator Name	Calibrator SMN	Assay	Tdef Name	Assay SMN	Onboard Storage Available	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)	C0 Adjust Pack Cal	Levels used in Lot Calibration	Calibrator Unopened Storage Temp	Calibrator Format (Lyophilized/Liquid)	Calibrator Volume (mL)
CH ENZ 3 CAL	11099319	Creatine Kinase	CK_L	11097640	Yes	30	202	21	—	2	2–8°C	Liquid	2.0
CH Fruc CAL	11099432	Fructosamine	Fruc	11097637	Yes	28	180	30	—	2	-15 to -25°C	Lyophilized	1.0
CH HDL/LDL CAL	11099402	Direct HDL Cholesterol	D_HDL	11097630	No	3	60	30	—	2	2–8°C	Lyophilized	1.0
		LDL Cholesterol Direct	DLDL	11097632	No	3	121	15	—	2	2–8°C	Lyophilized	1.0
CH hsCRP CAL	11099412	High Sensitivity C-Reactive Protein	hsCRP	11097633	Yes	60	60	30	—	6	2–8°C	Liquid	1.0
CH Lp(a) CAL	11099433	Lipoprotein(a)	Lp(a)	11097627	Yes	14	60	30	—	6	2–8°C	Lyophilized	1.0
CH LSP CAL	11099434	Alpha-1-acid Glycoprotein	AAG	11097629	Yes	28	60	14	—	6	2–8°C	Liquid	1.0
		Alpha-1-antitrypsin	AAT	11097628	Yes	28	60	7	—	6	2–8°C	Liquid	1.0
		Anti-Streptolysin-O_2	ASO_2	11097634	Yes	28	60	30	—	2	2–8°C	Liquid	1.0
		Complement C3	C3	11097624	Yes	28	60	14	—	6	2–8°C	Liquid	1.0
		Complement C4	C4	11097623	Yes	28	60	14	—	6	2–8°C	Liquid	1.0
		Haptoglobin	Hapt	11097643	Yes	28	10	30	—	6	2–8°C	Liquid	1.0
CH LSP CAL	11099434	Immunoglobulin A_2	IgA_2	11097619	Yes	28	60	30	—	6	2–8°C	Liquid	1.0
CH LSP CAL	11099434	Immunoglobulin G_2	IgG_2	11097616	Yes	28	60	30	—	6	2–8°C	Liquid	1.0
		Immunoglobulin M_2	IgM_2	11097620	Yes	28	60	30	—	6	2–8°C	Liquid	1.0
		Prealbumin	PreAlb	11097617	Yes	28	60	7	—	6	2–8°C	Liquid	1.0
		Rheumatoid Factor	RF	11097618	Yes	28	60	14	—	6	2–8°C	Liquid	1.0
		Transferrin	Trf	11097613	Yes	28	60	14	—	6	2–8°C	Liquid	1.0
CH MetMtb CAL	11099437	Methadone Metabolite (EDDP)	MetMtb	11097527	Yes	30	60	14	—	1	2–8°C	Liquid	10.0
CH SPCL CHEM CAL	11099438	Amylase_2	AMY_2	11097649	Yes	7	62	31	—	2	2–8°C	Lyophilized	5.0
		Lactate	Lac	11097614	Yes	7	62	30	—	2	2–8°C	Lyophilized	5.0
		Total Iron Binding Capacity	TIBC	11097525	Yes	7	180	7	—	2	2–8°C	Lyophilized	5.0
CH TDM CAL	11099439	Digoxin	Dgn	11097526	Yes	7 when protected from light	60	7	—	6	2–8°C	Lyophilized	3.0

Calibrator Name	Calibrator SMN	Assay	Tdef Name	Assay SMN	Onboard Storage Available	Calibrator Open Vial Stability (days)**	Lot Calibration Interval (days)	Pack Calibration Interval (days)	C0 Adjust Pack Cal	Levels used in Lot Calibration	Calibrator Unopened Storage Temp	Calibrator Format (Lyophilized/Liquid)	Calibrator Volume (mL)
CH TOX CAL	11099440	Acetaminophen	Acet	11097522	No	3	62	1	C0ADJUST	2	2–8°C	Liquid	3.0
		Ethyl Alcohol	ETOH	11097501	No	3	60	1	C0ADJUST	2	2–8°C	Liquid	3.0
		Salicylate	Sal	11097523	No	3	180	21	—	2	2–8°C	Liquid	3.0
CH UPro CAL	11099441	Total Protein_2 (urine)	Upro (urine)	11097524	No	21	60	30	—	2	2–8°C	Liquid	5.0
CH µALB_2 CAL	11099435	Microalbumin_2	µALB_2	11097610	No	60	180	30	—	6	2–8°C	Liquid	5.0
CH CYSC_2 CAL	11097648	Cystatin C_2	CYSC_2	11097647	Yes	60	61	40	—	6	2–8°C	Liquid	2.0
Emit 2000 Tacrolimus Calibrators	10445399	Tacrolimus	TACR	11097542	No	56	64	10	—	6	≤ -10°C	Liquid	2.0
—	—	Amylase	Amy	11097603	No	Fixed Factor	N/A	1	C0ADJUST	1	2–8°C	N/A	—
—	—	Pancreatic Amylase	PAmy	11097622	No	Fixed Factor	N/A	1	C0ADJUST	1	2–8°C	N/A	—

A-Lyte IMT Summary

This document applies to system software version 1.24. Assay availability is dependent on regulatory status in each country.

The Instructions For Use (IFU) is the primary source for assay details and should always be consulted for the most up-to-date information.

Serum, Lithium Heparin Plasma Test Definitions

Assay (TDef name)	Test Duration (sec)	Assay Principle	Calibration Interval	Sample Volume (µL)	Analytical Measuring Range	Significant Figures	Expected Values	Extended Range
Cl (serum/plasma)	18	Indirect Integrated Multisensor Technology (IMT)	automatic calibration every 4 hours	25	50–200 mmol/L (50–200 mEq/L)	3	Serum 98–107 mmol/L (Serum 98–107 mEq/L) Plasma 98–107 mmol/L (Plasma 98–107 mEq/L)	—
K (serum/plasma)	18	Indirect Integrated Multisensor Technology (IMT)	automatic calibration every 4 hours	25	1–10 mmol/L (1–10 mEq/L)	3	Serum 3.5–5.1 mmol/L (Serum 3.5–5.1 mEq/L) Plasma 3.4–4.5 mmol/L (Plasma 3.4–4.5 mEq/L)	—
Na (serum/plasma)	18	Indirect Integrated Multisensor Technology (IMT)	automatic calibration every 4 hours	25	50–200 mmol/L (50–200 mEq/L)	3	Serum 136–145 mmol/L (Serum 136–145 mEq/L) Plasma 136–145 mmol/L (Plasma 136–145 mEq/L)	—

Urine Test Definitions

Assay (TDef name)	Test Duration (sec)	Assay Principle	Calibration Interval	Sample Volume (µL)	Analytical Measuring Range	Significant Figures	Expected Values	Extended Range
Cl (urine)	27	Indirect Integrated Multisensor Technology (IMT)	automatic calibration every 4 hours	25	20–330 mmol/L	3	110–250 mmol/L/24 hr (110–250 mEq/L/24 hr)	2-fold manual urine dilution
K (urine)	27	Indirect Integrated Multisensor Technology (IMT)	automatic calibration every 4 hours	25	2–300 mmol/L	3	25–125 mmol/L/24 hr (25–125 mEq/L/24 hr)	2-fold manual urine dilution
Na (urine)	27	Indirect Integrated Multisensor Technology (IMT)	automatic calibration every 4 hours	25	10–300 mmol/L	3	40–220 mmol/L/24 hr (40–220 mEq/L/24 hr)	2-fold manual urine dilution

A-Lyte IMT Fluids

SMN	Material	Packaging	Onboard Stability	Storage Temp
11099304	Standard A	2 x 1.5L	30 days	2–30°C
11099306	Standard B	2 x Standard B: 250 mL	30 days	2–30°C
	Salt Bridge Solution	2 x Salt Bridge: 125 mL	30 days	2–30°C
11099315	A-LYTE Integrated Multisensor (IMT Na K Cl)	4 multisensors per carton	14 days or 5000 samples per multisensor	2–8°C
11099305	A-LYTE IMT Diluent	2 x 1.5L	90 days	2–30°C
11099325	Dilution Check	6 x 2 mL	Single Use Only	2–30°C

Assay availability is dependent on regulatory status in each country.
Footnotes begin on page 25.

Interferences Summary

This document applies to system software version 1.24. Assay availability is dependent on regulatory status in each country.
The Instructions For Use (IFU) is the primary source for assay details and should always be consulted for the most up-to-date information.

NOTE: Only serum and plasma sample types are supported for HIL.

Assay (TDef Name)	Hemolysis	Icterus	Lipemia	H Index	I Index	L Index
Acetaminophen (Acet)	≤ 6% change up to 500 mg/dL of hemoglobin	≤ 12% change up to 10 mg/dL of bilirubin	≤ -14% change up to 500 mg/dL of Intralipid	3	1	3
Alanine Aminotransferase (ALT)	≤ 10% at 450 mg/dL (0.28 mmol/L) of hemoglobin	≤ 10% at 30 mg/dL (513 µmol/L) of bilirubin, conjugated ≤ 10% at 30 mg/dL (513 µmol/L) of bilirubin, unconjugated	≤ 10% at 450 mg/dL (5.09 mmol/L) of Intralipid	3	4	3
Alanine Aminotransferase P5P (ALTPLc)	≤ 10% at 200 mg/dL (0.12 mmol/L) of hemoglobin	≤ 10% at 20 mg/dL (342 µmol/L) of bilirubin, conjugated ≤ 10% at 20 mg/dL (342 µmol/L) of bilirubin, unconjugated	≤ 10% at 400 mg/dL (4.5 mmol/L) of Intralipid	2	3	2
Albumin BCG (Alb)	≤ 10% at 400 mg/dL (0.25 mmol/L) of hemoglobin	≤ 10% at 30 mg/dL (513 µmol/L) of bilirubin, conjugated ≤ 10% at 30 mg/dL (513 µmol/L) of bilirubin, unconjugated	≤ 10% at 1000 mg/dL (11.3 mmol/L) of Intralipid	3	4	5
Albumin BCP (AlbP)	≤ 10% at 600 mg/dL (0.37 mmol/L) of hemoglobin	≤ 10% at 30 mg/dL (513 µmol/L) of bilirubin, conjugated ≤ 10% at 30 mg/dL (513 µmol/L) of bilirubin, unconjugated	≤ 10% at 500 mg/dL (5.65 mmol/L) of Intralipid	4	4	3
Alkaline Phosphatase, Concentrated (ALP_2c)	≤ 10% at 1000 mg/dL of hemoglobin	≤ 10% at 80 mg/dL of bilirubin	≤ 10% at 600 mg/dL of Intralipid	6	6	3
Alpha-1-acid Glycoprotein (AAG)	≤ 10% at 1000 mg/dL of hemoglobin	≤ 10% at 60 mg/dL of bilirubin	≤ 10% at 1000 mg/dL of Intralipid	6	6	5
Alpha-1-antitrypsin (AAT)	≤ 10% change up to 1000 mg/dL of hemoglobin.	≤ 10% change up to 25 mg/dL of bilirubin	≤ 10% change up to 125 mg/dL of Intralipid.	6	3	1
Ammonia (Amm)	18% bias at 375 mg/dL of hemoglobin	18% bias at 60 mg/dLof bilirubin	≤ 10% at 200 mg/dL of Intralipid	1	3	1
Amylase (Amylas) serum/plasma	≤ 10% at 525 mg/dL (0.336 mmol/L) of hemoglobin	≤ 10% at 30 mg/dL (513 µmol/L) of bilirubin, conjugated ≤ 10% at 30 mg/dL (513 µmol/L) of bilirubin, unconjugated	≤ 10% at 650 mg/dL (7.35 mmol/L) of Intralipid	4	4	3
Amylase_2 (AMY_2)	< 10% change up to 500 mg/dL of hemoglobin.	< 10% change up to 30 mg/dL of bilirubin.	< 10% change up to 650 mg/dL of Intralipid	4	4	3
Anti-Streptolysin-O_2 (ASO_2)	≤ 10% change up to 1000 mg/dL of hemoglobin.	≤ 10% change up to 60 mg/dL of bilirubin	≤ 10% change up to 1000 mg/dL of Intralipid.	6	6	5

Assay (TDef Name)	Hemolysis	Icterus	Lipemia	H Index	I Index	L Index
Apolipoprotein A-1 (APO A1)	≤ 10% change up to 525 mg/dL of hemoglobin.	≤ 10% change up to 30 mg/dL of bilirubin	≤ 10% change up to 650 mg/dL of Intralipid.	4	4	3
Apolipoprotein B (APO B)	≤ 10% change up to 525 mg/dL of hemoglobin.	≤ 10% change up to 30 mg/dL of bilirubin	≤ 10% change up to 650 mg/dL of Intralipid.	4	4	3
Aspartate Aminotransferase (AST)	Avoid hemolyzed samples	≤ 10% at 30 mg/dL (513 µmol/L) of bilirubin, conjugated ≤ 10% at 30 mg/dL (513 µmol/L) of bilirubin, unconjugated	≤ 10% at 400 mg/dL (4.52 mmol/L) of Intralipid	—	4	2
Aspartate Aminotransferase P5P (ASTPLc)	Avoid hemolyzed samples	≤ 10% at 20 mg/dL (342 µmol/L) of bilirubin, conjugated ≤ 10% at 20 mg/dL (342 µmol/L) of bilirubin, unconjugated	≤ 10% at 200 mg/dL (2.26 mmol/L) of Intralipid	—	3	1
Calcium (Arsenazo) (CA_2) serum/plasma	≤ 10% change up to 1000 mg/dL of hemoglobin.	≤ 10% change up to 50 mg/dL of conjugated bilirubin and 50 mg/dL of unconjugated bilirubin.	≤ 10% change up to 1000 mg/dL of Intralipid	6	5	5
Calcium (CPC) (Ca) serum/plasma	≤ 10% at 1000 mg/dL (0.62 mmol/L) of hemoglobin	≤ 10% at 30 mg/dL (513 µmol/L) of bilirubin, conjugated ≤ 10% at 30 mg/dL (513 µmol/L) of bilirubin, unconjugated	≤ 10% at 650 mg/dL (7.35 mmol/L) of Intralipid	6	4	3
Carbamazepine (Carb)	≤ 2% change up to 500 mg/dL of hemoglobin	0% change up to 20 mg/dL of bilirubin	≤ 8% change up to 800 mg/dL of Intralipid	4	3	4
Carbon Dioxide, Concentrated (CO2_c)	≤ 10% at 600 mg/dL of hemoglobin	≤ 10% at 30 mg/dL of bilirubin	≤ 10% at 750 mg/dL of Intralipid	4	4	4
Cholesterol_2 (Chol_2)	≤ 10% at 500 mg/dL (0.311 mmol/L) of hemoglobin	≤ 10% at 60 mg/dL (1026 µmol/L) of bilirubin, conjugated ≤ 10% at 20 mg/dL (342 µmol/L) of bilirubin, unconjugated	≤ 10% at 1000 mg/dL (11.3 mmol/L) of Intralipid	4	3	5
Cholinesterase (CHE)	≤ 10% at 500 mg/dL of hemoglobin	≤ 10% at 25 mg/dL of bilirubin	≤ 10% at 500 mg/dL of Intralipid	4	3	3
Chloride (Cl) serum/plasma	≤ 10% at 750 mg/dL (0.47 mmol/L) of hemoglobin	≤ 10% at 60 mg/dL (1026 µmol/L) of bilirubin, conjugated and unconjugated	≤ 10% at 3000 mg/dL (33.9 mmol/L) of Intralipid	5	6	6
Complement C3 (C3)	≤ 10% at 1000 mg/dL of hemoglobin	≤ 10% at 25 mg/dL of bilirubin, conjugated ≤ 10% at 18.8 mg/dL of bilirubin, unconjugated	≤ 10% at 1000 mg/dL of Lipemia (avian triglycerides)	6	2	5
Complement C4 (C4)	≤ 10% at 750 mg/dL of hemoglobin	≤ 10% at 18.8 mg/dL of bilirubin, conjugated ≤ 10% at 18.8 mg/dL of bilirubin, unconjugated	≤ 10% at 1000 mg/dL of Lipemia (avian triglycerides)	5	2	5
C-Reactive Protein_2 (CRP_2)	≤ 10% at 1000 mg/dL of hemoglobin	≤ 10% at 60 mg/dL of bilirubin, conjugated ≤ 10% at 60 mg/dL of bilirubin, unconjugated	≤ 10% at 1000 mg/dL of Intralipid	5	6	5

Assay (TDef Name)	Hemolysis	Icterus	Lipemia	H Index	I Index	L Index
Creatine Kinase (CK_L)	≤ 10% at 125 mg/dL (1.25 g/L) of hemoglobin	≤ 10% at 60 mg/dL (1026 µmol/L) of bilirubin, conjugated ≤ 10% at 60 mg/dL (1026 µmol/L) of bilirubin, unconjugated	≤ 10% at 1000 mg/dL (11.3 mmol/L) of Intralipid	1	6	5
Creatinine_2 (Crea_2) serum/plasma	Do not use hemolyzed samples ≤ 10% at 500 mg/dL (0.311 mmol/L) of hemoglobin	≤ 10% at 20 mg/dL (342 µmol/L) of bilirubin, conjugated ≤ 10% at 10 mg/dL (171 µmol/L) of bilirubin, unconjugated	≤ 10% at 500 mg/dL (5.65 mmol/L) of Intralipid	4	2	3
Cystatin C_2 (CYSC_2)	≤ 10% change up to 1000 mg/dL of hemoglobin.	≤ 10% change up to 60 mg/dL of conjugated bilirubin and 60 mg/dL of unconjugated bilirubin.	≤ 10% change up to 1000 mg/dL of Intralipid.	6	6	5
Digoxin (Dgn)	≤ 8% change up to 500 mg/dL of hemoglobin	≤ 7% change up to 60 mg/dL of bilirubin	≤ 9% change up to 399 mg/dL of Intralipid	4	6	2
Direct Bilirubin 2 (DBil_2)	≤ 10% change up to 1000 mg/dL of hemoglobin.	—	≤ 10% change up to 750 mg/dL of Lipemia (Triglycerides Concentrate)	6	—	4
Direct HDL Cholesterol (D-HDL)	≤ 10% at 500 mg/dL of hemoglobin	≤ 10% at 30 mg/dL of bilirubin	≤ 10% at 1000 mg/dL of Intralipid	4	4	5
Enzymatic Creatinine_2 (ECre_2)	< 10% at 750 mg/dL of hemoglobin	< 10% at 30 mg/dL of bilirubin	< 10% at 1000 mg/dL of Intralipid	5	4	5
Enzymatic Hemoglobin A1c (A1c_E)	—	< 5% change up to 10 mg/dL of Bilirubin, conjugated and unconjugated	< 5% change up to 1000 mg/dL of Intralipid	—	—	—
Ethyl Alcohol (ETOH)	≤ 6% change up to 1000 mg/dL of hemoglobin	≤ 4% change up to 80 mg/dL of bilirubin	≤ 1% change up to 3000 mg/dL of Intralipid	6	6	6
Fructosamine (Fruc)	≤ 3% change up to 750 mg/dL of hemoglobin.	≤ 8% change up to 5 mg/dL of conjugated bilirubin; ≤ 8% change up to 7.5 mg/dL of unconjugated bilirubin	≤ 6% change up to 1000 mg/dL of Trig.	3	1	5
Gamma-Glutamyl Transferase (GGT)	≤ 10% at 1000 mg/dL of hemoglobin	≤ 10% at 10 mg/dL of bilirubin	≤ 10% at 500 mg/dL of Intralipid	5	2	3
Gentamicin (Gent)	≤ 2% change up to 500 mg/dL of hemoglobin	≤ 2% change up to 20 mg/dL of bilirubin	≤ 6% change up to 1000 mg/dL of Intralipid	4	3	5
Glucose Hexokinase_3 (GluH_3)	≤ 10% change up to 1000 mg/dL of hemoglobin.	≤ 10% change up to 30 mg/dL of bilirubin	≤ 10% change up to 1000 mg/dL of Intralipid.	6	4	5
Glucose Oxidase (GluO)	≤ 10% change up to 200 mg/dL of hemoglobin.	≤ 10% change up to 7.5 mg/dL of bilirubin	≤ 10% change up to 250 mg/dL of Intralipid.	2	1	2
Haptoglobin (Hapt)	≤ 10% change up to 125 mg/dL of hemoglobin	≤ 10% change up to 25 mg/dL of bilirubin	≤ 10% change up to 1000 mg/dL of Intralipid.	0	3	5
High Sensitivity C-Reactive Protein (hsCRP)	≤ 10% change up to 500 mg/dL of hemoglobin.	≤ 10% change up to 30 mg/dL of bilirubin	≤ 10% change up to 1000 mg/dL of Intralipid.	1	4	3

Assay (TDef Name)	Hemolysis	Icterus	Lipemia	H Index	I Index	L Index
Immunoglobulin A_2 (IgA_2)	<10% up to 1000 mg/dL of hemoglobin	<10% up to 50 mg/dL of bilirubin	<10% up to 922 mg/dL of Trig; <10% up to 500 mg/dL of Intralipid.	4	3	3
Immunoglobulin G_2 (IgG_2)	<10% up to 1000 mg/dL of hemoglobin	<10% up to 50 mg/dL of bilirubin	<10% up to 1000 mg/dL of Intralipid.	6	5	5
Immunoglobulin M_2 (IgM_2)	<10% up to 1000 mg/dL of hemoglobin	<10% up to 60 mg/dL of bilirubin	<10% up to 1000 mg/dL of Intralipid.	6	6	5
Inorganic Phosphorus (IP)	≤ 10% at 500 mg/dL of hemoglobin	≤ 10% at 30 mg/dL of bilirubin	≤ 10% at 650 mg/dL of Intralipid	4	4	1
Iron_2 (Iron_2)	—	<10% up to 50 mg/dL of bilirubin	<10% up to 500 mg/dL of Intralipid.	—	5	3
Lactate (Lac)	<10% up to 300 mg/dL of hemoglobin	<10% up to 3.75 mg/dL of bilirubin	<10% up to 1000 mg/dL of Intralipid.	3	1	5
Lactate_2 (Lac_2)	<10% up to 1000 mg/dL of hemoglobin	<10% up to 9.2 mg/dL of bilirubin	<10% up to 1000 mg/dL of Intralipid.	3	1	5
Lactate Dehydrogenase L-P (LDLP)	—	≤ 10% at 30 mg/dL of bilirubin	≤ 10% at 650 mg/dL of Intralipid	—	4	3
LDL Cholesterol Direct (DLDL)	≤ 10% at 810 mg/dL of hemoglobin	≤ 10% at 20 mg/dL of conjugated bilirubin ≤ 10% at 30 mg/dL of unconjugated bilirubin	≤ 10% at 505 mg/dL of Intralipid	5	3	3
Lidocaine (LIDO)	≤ 10% interference up to 375 mg/dL of hemoglobin at analyte concentration 5.1 and 8.3 µg/mL	≤ 10% interference up to 60 mg/dL of Bilirubin, conjugated at analyte concentration 5.0 and 8.0 µg/mL; ≤ 10% interference up to 60 mg/dL of Bilirubin, unconjugated at analyte concentration 5.0 and 8.1 µg/mL;	≤ 10% interference up to 1000 mg/dL of Lipemia (Intralipid) at analyte concentration 5.0 and 8.0 µg/mL	3	6	5
Lipase (Lip)	<10% up to 200 mg/dL of hemoglobin	<10% up to 25 mg/dL of bilirubin	<10% up to 1000 mg/dL of Intralipid.	2	3	5
Lipoprotein(a) (Lp(a))	≤ 10% change up to 1000 mg/dL of hemoglobin.	≤ 10% change up to 60 mg/dL of bilirubin	≤ 10% change up to 1000 mg/dL of Intralipid.	6	3	3
Lithium (Li)	≤ 7% change up to 750 mg/dL of hemoglobin	≤ -8% change up to 40 mg/dL of bilirubin	≤ -4% change up to 500 mg/dL of Intralipid	5	5	3
Lithium_2 (LITH_2)	≤ 7% change up to 750 mg/dL of hemoglobin	≤ -8% change up to 40 mg/dL of bilirubin	≤ -4% change up to 500 mg/dL of Intralipid	5	5	3
Magnesium (Mg)	<10% up to 750 mg/dL of hemoglobin	<10% up to 30 mg/dL of bilirubin	<10% up to 500 mg/dL of Intralipid.	4	4	3
Magnesium (Mg)	<10% up to 750 mg/dL of hemoglobin	<10% up to 30 mg/dL of bilirubin	<10% up to 500 mg/dL of Intralipid.	4	4	3

Assay (TDef Name)	Hemolysis	Icterus	Lipemia	H Index	I Index	L Index
N-Acetylprocainamide (NAPA)	≤ 10% interference from up to 500 mg/dL hemoglobin at analyte concentration of 9.8 and 14.4 µg/mL	≤ 10% interference from up to 60 mg/dL Bilirubin, conjugated at analyte concentration of 9.4 and 14.3 µg/mL; ≤ 10% interference from up to 60 mg/dL Bilirubin, unconjugated at analyte concentration of 9.8 and 14.5 µg/mL;	≤ 10% interference from up to 1000 mg/dL Lipemia (Intralipid) at analyte concentration of 9.7 and 14.4 µg/mL	4	6	5
Pancreatic Amylase (PAmy)	≤ 10% at 500 mg/dL of hemoglobin	≤ 10% at 25 mg/dL of bilirubin	≤ 10% at 1000 mg/dL of Intralipid	4	3	5
Phenobarbital (Phnb)	≤ 5% change up to 500 mg/dL of hemoglobin	≤ 6% change up to 80 mg/dL of bilirubin	≤ 10% change up to 200 mg/dL of Intralipid	4	6	1
Phenytoin (Phny)	≤ 9% change up to 300 mg/dL of hemoglobin	≤ 4% change up to 20 mg/dL of bilirubin	≤ 7% change up to 250 mg/dL of Intralipid	3	3	2
Potassium (K) serum/plasma	—	≤ 10% at 60 mg/dL (1026 µmol/L) of bilirubin, conjugated and unconjugated	≤ 10% at 3000 mg/dL (33.9 mmol/L) of Intralipid	1	6	6
Prealbumin (PreAlb)	≤ 10% change up to 1000 mg/dL of hemoglobin.	≤ 10% change up to 25 mg/dL of bilirubin	≤ 10% change up to 250 mg/dL of Intralipid.	6	3	2
Procainamide (PROC)	≤ 10% interference from up to 500 mg/dL hemoglobin at analyte concentration 5.8 and 9.7 µg/mL	≤ 10% interference from up to 60 mg/dL Bilirubin, conjugated at analyte concentration 5.6 and 9.5 µg/mL; ≤ 10% interference from up to 60 mg/dL Bilirubin, unconjugated at analyte concentration 5.8 and 9.5 µg/mL	≤ 10% interference from up to 1000 mg/dL Lipemia (Intralipid) at analyte concentration 5.7 and 9.5 µg/mL	4	6	5
Rheumatoid Factor (RF)	≤ 10% change up to 1000 mg/dL of hemoglobin.	≤ 10% change up to 25 mg/dL of bilirubin	≤ 10% change up to 1000 mg/dL of Intralipid.	2	3	5
Salicylate (Sal)	≤ -9% change up to 1000 mg/dL of hemoglobin	≤ -9% change up to 30 mg/dL of bilirubin	≤ -5% change up to 1000 mg/dL of Intralipid	4	2	4
Sodium (Na) serum/plasma	<10% up to 750 mg/dL of hemoglobin	≤ 10% at 60 mg/dL (1026 µmol/L) of bilirubin, conjugated and unconjugated	≤ 10% at 3000 mg/dL (33.9 mmol/L) of Intralipid	5	6	6
Tacrolimus (TACR)	—	≤ 10% interference up to 45 mg/dL bilirubin, conjugated (Tacrolimus concentration 9.1 and 15.2 ng/mL); ≤ 10% interference up to 60 mg/dL bilirubin, uncconjugated (Tacrolimus concentration 8.7 and 13.6 ng/mL);	≤ 10% interference up to 1125 mg/dL Lipemia (Intralipid) (Tacrolimus concentration 8.9 and 16.6 ng/mL)	—	—	—
Theophylline (Theo)	≤ -3% change up to 1000 mg/dL of hemoglobin	≤ 4% change up to 80 mg/dL of bilirubin	≤ 10% change up to 1000 mg/dL of Intralipid	6	6	5
Tobramycin (Tob)	≤ 2% change up to 500 mg/dL of hemoglobin	≤ 2% change up to 20 mg/dL of bilirubin	≤ 4% change up to 800 mg/dL of Intralipid	4	3	4
Total Bilirubin_2 (TBil_2)	<10% up to 1000 mg/dL of hemoglobin	—	≤10% up to 750 mg/dL of Lipemia (Triglycerides concentrate)	4	—	4

Assay (TDef Name)	Hemolysis	Icterus	Lipemia	H Index	I Index	L Index
Total Iron Binding Capacity (TIBC)	<10% up to 1000 mg/dL of hemoglobin	<10% up to 25 mg/dL of bilirubin	<10% up to 1000 mg/dL of Trig; <10% up to 375 mg/dL of Intralipid.	6	2	2
Total Protein II (TP)	<10% up to 500 mg/dL of hemoglobin	<10% up to 25 mg/dL of bilirubin	<10% up to 500 mg/dL of Intralipid.	4	3	3
Transferrin (Trf)	<10% up to 525 mg/dL of hemoglobin	<10% up to 30 mg/dL of bilirubin	<10% up to 650 mg/dL of Intralipid.	4	4	3
Triglycerides (concentrated) (Trig)	<10% up to 1000 mg/dL of hemoglobin	<10% up to 30 mg/dL of bilirubin	—	4	1	—
Urea Nitrogen (UN_c)	<10% up to 500 mg/dL of hemoglobin	<10% up to 30 mg/dL of bilirubin	<10% up to 650 mg/dL of Intralipid.	2	3	3
Uric Acid (UA)	<10% up to 250 mg/dL of hemoglobin	<10% up to 30 mg/dL of bilirubin	<10% up to 1000 mg/dL of Trig.	1	2	5
Valproic Acid (VPA)	6% bias up to 1000 mg/dL (0.62 mmol/L) of hemoglobin	≤ 1% bias up to 80 mg/dL of bilirubin	4% bias up to 1000 mg/dL (11.3 mmol/L) of Intralipid	6	6	5
Vancomycin (Vanc)	≤ 2.1% change up to 600 mg/dL of hemoglobin	≤ 0.9% change up to 20 mg/dL of bilirubin	≤ 2.7% change up to 1000 mg/dL of Intralipid	4	3	5
β2-Microglobulin (B2M)	≤ 10% at 1000 mg/dL of hemoglobin	≤ 10% at 60 mg/dL of bilirubin, conjugated ≤ 10% at 60 mg/dL of bilirubin, unconjugated	≤ 10% at 1000 mg/dL of Intralipid	4	6	5
Emit® Amikacin Assay (Alliance Application)	No clinically significant interference has been found in samples with up to 800 mg/dL hemoglobin	No clinically significant interference has been found in samples with up to 30 mg/dL bilirubin	No clinically significant interference has been found in samples with up to 1000 mg/dL triglycerides	5	4	5

Trademark Information

Footnotes

*	Dilution factor refers to dilutions that extend the upper limit of the measuring interval. See assay instructions for use for dilution factors that extend below the lower limit of the measuring interval.
**	Stability of opened or reconstituted calibrator stored in a laboratory refrigerator, per Instructions for Use. Stability of calibrators stored in the Cal/QC Storage area of the Sample Handler may differ. For stability of calibrators stored onboard the Sample Handler, refer to 11111053 Atellica Sample Handler Calibrator and QC Storage and Stability.
Δ	See assay instructions for use.
†	Requires manual preparation. See assay instructions for use.
††	All measurements are in ng/mL unless otherwise listed.
‡	The level number assigned in the calibrator definition in comparison to the printed level on the barcode labels may differ. Refer to the color-coded information for clarification.

Level 1	Level 2	Level 3	Level 4	Level 5

Notes

All assays may not be available. Contact the local technical support provider for availability.
The information in the printed customer documentation was correct at the time of issue. Siemens Healthineers continues to improve products and reserves the right to change specifications, equipment, and maintenance procedures at any time without notice. For current information, see the assay Instruction For Use (IFU) available at www.siemens-healthineers.com.